Vir Biotechnology Audit Committee Chair Ramasastry resigns over business conflict

Filed May 28, 2026 · Period ending May 25, 2026 · ~1 min read

Key Changes

• medium

  Audit Committee Chair Saira Ramasastry resigned from the Board effective May 26, 2026, citing a business conflict. The company stated her departure was not due to any disagreement on operations, policies, or practices.

  Item 5.02 verify on EDGAR →
• medium

  Robert More was immediately appointed as new Audit Committee Chair following Ramasastry's departure. The Board reduced its size from eight to seven members with no immediate replacement planned.

  Item 5.02 verify on EDGAR →
• low

  At the 2026 Annual Meeting, stockholders elected three Class I directors (More, Napolitano, Sigal) to serve until 2029, approved executive compensation on an advisory basis, and ratified Ernst & Young as auditor.

  Item 5.07 verify on EDGAR →